CD38 and chronic myelogenous leukemia, BCR-ABL1 positive: As expected, MS023 treatment dramatically decreased the H4R3me2a level and imatinib reduced the p‐BCR‐ABL level in primary CML CD34+CD38− cells (Figure S1A, Supporting Information).